Analysis of the Medication Characteristics of Breviscapine Injection in the Real World

doi:10.19803/j.1672-8629.2021.08.04

Abstract

Abstract: Objective To explore the demographic characteristics and patterns of medication among patients using breviscapine injection in the real world. Methods The medical data on patients treated with breviscapine injection was retrieved from the information system of 34 tertiary hospitals from January 1, 2002 to December 31, 2015 in China. After normalization, a model was established using the Apriori algorithm, and association rule analysis was carried out with Clementine12.0 software. Results Most of the 48 710 patients were between 45 and 64 years old (34.66%), and male patients outnumbered female ones. Departments of Orthopedics (19.14%) and Cardiology(14.83%) were the biggest users of the drug. The top three diagnoses by Western medicine were essential hypertension (19.33%),coronary heart disease (12.39%),and cerebral infarction (11.25%),while the dominating syndromes diagnosed by TCM were liver and kidney Yin deficiency syndrome (17.29%),followed by qi stagnation and blood stasis syndrome (16.60%),and phlegm and blood stasis syndrome (8.78%). The route of administration was mostly intravenous drip, and the single dose was mostly 20-50mg (51.47%).The most frequent combination with western medicines involved acetylsalicylic acid (4.59%) and heparin (3.04%) , compared with compound salvia miltiorrhiza dropping pills (2.12%) and Simo decoction (1.84%) from TCM. Conclusion The results showed that the patients with breviscapine injection were mainly middle-aged and elderly patients, and the indications were basically in line with the instructions, but there were still off-label drug use (orthopedic disease treatment), and the proportion of off-label dose in actual clinical use was relatively high, it is necessary to strengthen the dosage specification and medication supervision. The clinical application should still refer to the instructions. Combined drug use is consistent with the guidelines and has certain rules to follow, which can provide clues for clinical medication.

Key words: breviscapine injection, real world, combined medication

CLC Number:

R994.11

WANG Yajiao, LI Yuanyuan, XIE Yanming, YANG Xiaochen. Analysis of the Medication Characteristics of Breviscapine Injection in the Real World[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 715-718.

References

[1] Lyu J, Xie YM, Sun MH, et al.Clinical evidence and GRADE assessment for breviscapine injection (DengZhanHuaSu) in patients with acute cerebral infarction[J]. Journal of Ethnopharmacology, 2020(4): 262-265.
[2] Wu LH, Gao YH, Zhang SF, et al.The effects of breviscapine injection on hypertension in hypertension-induced renal damage patients: a systematic review and a meta-analysis[J]. Frontiers in Pharmacology, 2019, 10: 118-122.
[3] Yan ZL, Zhi YL, Xiao HL, et al.Effect of breviscapine against hepatic ischemia reperfusion injury[J]. Journal of Surgical Research, 2016, 203(2): 268-274.
[4] Gao JL, Chen G, He HQ, et al.Therapeutic effects of breviscapine in cardiovascular diseases: a review[J]. Front Pharmacol, 2017, 8: 289.
[5] Li YY, Guo RJ, Xie YM, et al.Expert consensus on clinical application of breviscapine for injection[J]. China Journal of Traditi-onal Chinese Medicine(中国中药杂志), 2020, 45(10): 2296-2299.
[6] Baumfeld AE, Reynolds Robert, Caubel P, et al.Trial designs using real-world data: The changing landscape of the regulatory approval process[J]. Pharmacoepidemiol Drug Saf, 2020, 29: 1201-1212.
[7] World Health Organization.International Statistical Classification of Diseases and Related Health Issues (10th Revision)[M]. 2nd Ed. Beijing: People's Medical Publishing House(国际疾病标准编码), 2008.
[8] Yaozhi Data.Drug ATC code query system [EB/OL]. [2021-05-10].https://db.yaozh.com/atc/.
[9] Schwartz JB, Schmader KE, Hanlon JT, et al.Pharmacotherapy in older adults with cardiovascular disease: report from an american college of cardiology, american geriatrics society, and national institute on aging workshop[J]. J Am Geriatr Soc, 2019, 67: 371-380.
[10] Liu X, Guo CY, Ma XJ, et al.Relationship between serum estrogen levels and blood stasis syndrome in postmenopausal women with coronary heart disease[J]. Pak J Med Sci, 2015, 31: 25-30.
[11] Zhang AZ. Traditional Chinese Orthopedics(中医骨伤学) [M].Shanghai: Shanghai Science and Technology Press, 1997: 33.
[12] Liao CZ.Breviscapine in the treatment of 45 cases of knee osteoar-thritis[J]. China Pharmaceutical(中国药业), 2015, 24(8): 88-89.
[13] Jin R, Wang YG, Xue CM, et al.Criterion and scale exploration of Chinese patent medicine prescription comment(4): indication inappropriateness[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2015, 35(13): 1161-1167.
[14] Pan ZW, Feng TM, Shan LC, et al.Scutellarin-induced endoth-elium-independent relaxation in rataorta[J]. Phytother Res, 2008, 22: 1428-1433.
[15] Wang Y, Fan LP, Song J, et al.Analysis and discussion on 74 cases of adverse reactions of TCM injection[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2018, 43(21): 4347-4351
[16] Cheng FJM, Xie YM, Wang LX, et al.Real-world study of the factors influencing suspected anaphylaxis of breviscapine for injection[J]. Journal of Traditional Chinese Medicine(中医杂志), 2020, 61(24): 2174-2178.
[17] Arnett DK, Blumenthal RS, Albert MA, et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines[J]. J Am Coll Cardiol, 2019, 74: e177-e232.
[18] Mo C, Sun G, Wang YZ, et al.PPI versus histamine h2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: systematic review and meta-analysis[J]. PLoS One, 2015, 10: e0131558.
[19] Salmoirago-Blotcher E, Crawford S, Jackson E, et al.Constipation and risk of cardiovascular disease among postmenopausal women[J]. Am J Med, 2011, 124: 714-23.
[20] Ruan XF, Li YJ, Ju CW, et al.Exosomes from Suxiao Jiuxin pill-treated cardiac mesenchymal stem cells decrease H3K27 demethylase UTX expression in mouse cardiomyocytes in vitro[J].Acta Pharmacol Sin, 2018, 39: 579-586.
[21] Lu DP, Wang YM, Yin KZ, et al.Analysis and utilization of 2011 annual report of adverse drug reaction monitoring[J]. China Pharmaceutical(中国药业), 2012, 21(22): 7-8.